ERBB2 and breast carcinoma: Conjugating the AURIF to anti-Her2 and anti-EGFR recombinant antibodies significantly improved the specificity of AURIF and increased its cytotoxicity by more than 30-fold toward Her2 expressing breast cancer cells [46].